Market Signal Briefing

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –

– Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting –

– Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 –

IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced its financial results for the quarter ended September 30, 2025, and provided a business update.

“The foundation of AEON’s progress lies in our science and is underscored by years of market validation”, said Rob Bancroft, AEON’s President and Chief Executive Officer. “Our recently released analytical results confirm both ABP-450’s identical amino-acid sequencing of all visible portions and highly similar functional characteristics to BOTOX®. These results are supported by a globally approved and fully scaled manufacturing platform with approvals in 69 countries. Together, these scientific and global data points validate our biosimilar strategy and instill confidence in AEON’s path forward.”

“On the strength of this foundation, we announced two complementary financing transactions with Daewoong Pharmaceutical and institutional investors that are expected to eliminate over 90% of our outstanding debt, strengthen our balance sheet, and extend our cash runway into the second quarter of 2026 while accelerating the ABP-450 program by up to six months. With our FDA Type 2a meeting scheduled later this month, we are entering the next phase of development from a position of scientific and financial strength.”

Recent Clinical and Corporate Highlights

Positive Biosimilarity Results In November 2025, AEON reported positive biosimilarity data for ABP-450, its proposed biosimilar to BOTOX®. Analytical results confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX®. The analytical package has been submitted to the FDA ahead of AEON’s Type 2a meeting scheduled for November 19, 2025. LC-MS analysis demonstrated that the primary structure of ABP-450 exhibited a 100% amino-acid sequence match to BOTOX®, with sequence coverage of 93–99% across all five proteins comprising the 900 kDa botulinum toxin type A complex. Strategic Financing and Note Exchange Also in November 2025, AEON announced two complementary transactions - a $6 million PIPE financing and a proposed Daewoong Pharmaceutical note exchange - which, together, are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90% and extend cash runway into the second quarter of 2026 while accelerating the ABP-450 program by up to six months. Liquidity and Capital Resources

The Company reported cash and cash equivalents of $5.9 million as of September 30, 2025, which does not include expected proceeds from the November 2025 PIPE financing. Including the recent financing, the company’s cash and cash equivalents are expected to be sufficient to fund the Company’s operating plan through into the second quarter of 2026, well beyond its Type 2a meeting with the FDA scheduled for this month. Expected Upcoming Milestones

November 19, 2025 – Expected results and path forward from Biosimilar Biological Product Development (BPD) Type 2a FDA meeting. About the U.S. Biosimilar Pathway

The U.S. Food and Drug Administration (“FDA”) regulates biosimilars under the Public Health Service Act’s 351(k) pathway, which require developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450 injection for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of completion of, or outcome of results from, primary comparative analytical studies, or potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan", "possible", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the completion of the primary structure analysis by AEON; (ii) the completion of select functional analyses by Daewoong Pharmaceutical; (iii) the expected Type 2a meeting with the FDA and potential path forward to biosimilarity designation; (iv) AEON’s ability to receive full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX on an accelerated timeline or at all; (v) the outcome of any legal proceedings that may be instituted against AEON or others; (vi) AEON’s future capital requirements; (vii) AEON’s ability to raise financing in the future; (viii) AEON’s ability to continue to meet continued stock exchange listing standards; (ix) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (x) the outcomes from any meetings or discussions with regulatory authorities; (xi) the timing of, or results from, any testing performed on AEON’s product; (xii) AEON’s ability to consummate the PIPE financing transaction and proposed notes exchange transaction in a timely manner and on the current terms; and (xiii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC’s website at www.sec.gov.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material in respect of obtaining the stockholder approval needed to consummate the PIPE financing and proposed not exchange transactions described above (the “Stockholder Approval”). In connection with obtaining the Stockholder Approval, the Company expects to file a proxy statement on Schedule 14A and other relevant materials with the SEC. This communication does not constitute a solicitation of any vote or approval. SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY ALL RELEVANT DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC, INCLUDING THE COMPANY’S PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTIONS. Copies of the proxy statement and other relevant materials and any other documents filed by the Company with the SEC may be obtained free of charge at the SEC’s website, at www.sec.gov. In addition, stockholders may obtain free copies of the proxy statement and other relevant materials through the website maintained by the SEC at http://www.sec.gov. or by directing a request to: AEON Biopharma, Inc., [email protected].

Participants in the Solicitation

The Company and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in respect of the Stockholder Approval. Information about the directors and executive officers of the Company is set forth in the Company's proxy statement on Schedule 14A filed with the SEC on April 29, 2025 and on subsequent Form 4 and Form 5 filings. Other information regarding the persons who may be deemed participants in the proxy solicitations in connection with the transactions, and a description of any interests that they have in the exchanges, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the Stockholder Approval when they become available. Stockholders, potential investors and other interested persons should read the proxy statement carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

Contacts

Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
[email protected]

Source: AEON Biopharma

 AEON BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data and par value amounts)  September 30, December 31, 2025
 2024
 (Unaudited)  ASSETS     Current assets:     Cash and cash equivalents$5,927  $13 Prepaid expenses and other current assets 1,485   1,577 Total current assets 7,412   1,590 Property and equipment, net 181   235 Operating lease right-of-use asset 1,112   1,288 Other assets 29   29 Total assets$8,734  $3,142 LIABILITIES AND STOCKHOLDERS' DEFICIT     Current liabilities:     Accounts payable$2,525  $5,910 Accrued clinical trials expenses 1,524   3,571 Accrued compensation 1,547   1,068 Other accrued expenses 2,632   3,600 Total current liabilities 8,228   14,149 Convertible notes at fair value, including related party amount of
$17,051 and $11,689, at September 30, 2025 and December 31, 2024,
respectively 17,051   11,689 Operating lease liability 957   1,145 Warrant liability 2,338   1,187 Contingent consideration liability 32   3,541 Total liabilities 28,606   31,711 Commitments and contingencies (Note 6)     Stockholders’ Deficit:     Class A common stock, $0.0001 par value; 1,040,000,000 and
500,000,000 shares authorized at September 30, 2025 and
December 31, 2024, and 11,643,786 and 555,511 shares issued and
outstanding at September 30, 2025 and December 31, 2024, respectively 9   4 Additional paid-in capital 413,801   403,024 Accumulated deficit (433,682)  (431,597)Total stockholders' deficit (19,872)  (28,569)Total liabilities and stockholders' deficit$8,734  $3,142          AEON BIOPHARMA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME(in thousands, except share and per share data)  Three Months Ended Nine Months Ended September 30, September 30, 2025
 2024
 2025
 2024
Operating expenses:           Selling, general and administrative$1,933  $3,044  $8,316  $11,014 Research and development 597   972   2,485   11,144 Change in fair value of contingent consideration (37)  —   (3,509)  (97,464)Total operating costs and expenses 2,493   4,016   7,292   (75,306)(Loss) income from operations (2,493)  (4,016)  (7,292)  75,306 Other (loss) income:           Change in fair value of convertible notes (1,877)  (1,878)  (5,362)  (170)Change in fair value of warrants (236)  (377)  85,950   (15,376)Loss on issuance of warrants —   —   (75,644)  — Loss on embedded forward purchase agreements
and derivative liabilities, net —   81   —   (19,931)Other income, net 68   19   263   94 Total other (loss) income, net (2,045)  (2,155)  5,207   (35,383)(Loss) income before taxes (4,538)  (6,171)  (2,085)  39,923 Income taxes —   —   —   — Net (loss) income$(4,538) $(6,171) $(2,085) $39,923 Basic net (loss) income per share$(0.39) $(11.24) $(0.23) $74.53 Diluted net (loss) income per share$(0.39) $(11.24) $(0.23) $69.53 Weighted average shares of common stock
outstanding used to compute basic net (loss) income
per share 11,634,946   549,175   8,931,566   535,693 Weighted average shares of common stock
outstanding used to compute diluted net (loss)
income per share 11,634,946   549,175   8,931,566   574,216                  The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its controlled subsidiaries.

-

PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (NYSE: CNK), one of the largest motion picture exhibitors in the world, today announced participation at the following institutional investor conferences:

Tuesday, November 18: Wells Fargo TMT Conference in Rancho Palos Verdes, CA

Melissa Thomas, CFO; Chanda Brashears, SVP Investor Relations

1:1 investor meetings

Fireside chat at 1:30 pm PT

https://cc.webcasts.com/well001/111825a_js/?entity=35_YDSUQJC

About Cinemark Holdings, Inc.:

Cinemark Holdings, Inc. (NYSE: CNK) provides extraordinary out-of-home entertainment experiences as one of the largest and most influential theatrical exhibition companies in the world. Based in Plano, Texas, Cinemark makes every day cinematic for moviegoers across nearly 500 theaters and over 5,500 screens, operating in 42 states in the U.S. (304 theaters; 4,249 screens) and 13 South and Central American countries (193 theaters; 1,395 screens). Cinemark offers guests superior sight and sound technology, including Barco laser projection and Cinemark XD, the world’s No. 1 exhibitor-branded premium large format; industry-leading penetration of upscale amenities such as expanded food and beverage offerings, Luxury Lounger recliners and D-BOX motion seats; top-notch guest service; and award-winning loyalty programs such as Cinemark Movie Club. All of this creates an immersive environment for a shared, entertaining escape, underscoring that there is no place more cinematic than Cinemark. For more information, visit https://ir.cinemark.com.

More News From Cinemark Holdings, Inc.

Back to Newsroom

Decades after their founders connected, Apple and Issey Miyake released a collection of phone pouches that have some people baffled. They hope it will inspire creativity.

Key Takeaways Agnico Eagle reported better-than-expected Q3 earnings but faced higher all-in sustaining costs.AEM expects 2025 AISC of $1,250-$1,300 per ounce, up from 2024 as cost pressures persist.Shares have surged 115.9% YTD, with EPS estimates for 2025 and 2026 trending higher.
Agnico Eagle Mines Limited (AEM - Free Report) delivered better-than-expected earnings in the third quarter, but it remains hamstrung by higher unit costs. Its all-in sustaining cost (AISC) — the most important cost metric of miners — was $1,373 per ounce in the third quarter, marking a roughly 6% increase from the prior quarter and a 7% year-over-year rise. AISC increased due to higher total cash costs and an uptick in general and administrative expenses. Total cash costs per ounce for gold were $994, up 8% from $921 a year ago and higher than $933 in the prior quarter.

Higher production costs warrant caution, as they will likely weigh on AEM’s profitability. This calls for prudent cost management to maintain competitiveness and sustain margins. AEM forecasts total cash costs per ounce in the range of $915 to $965 and AISC per ounce between $1,250 and $1,300 for 2025, suggesting a year-over-year increase at the midpoint of the respective ranges.

While Agnico Eagle is taking actions to control costs, the inflationary pressure is likely to continue over the near term, weighing on its overall financial performance. AISC is likely to rise in the latter part of 2025 as deferred expenditures are realized. Maintaining its cost discipline will be crucial for the company to sustain its margin expansion.

Among AEM’s peers, Newmont Corporation (NEM - Free Report) lowered its third-quarter AISC to $1,566 per ounce, marking a 3% decrease from the prior-year quarter and a decline from $1,593 in the prior quarter. This improvement was primarily due to a decline in costs applicable to sales and lower general and administrative expenses, as Newmont is enjoying the benefits from its cost-saving actions. Newmont expects gold AISC for the total portfolio to be $1,630 per ounce in 2025, reflecting a rise from $1,516 per ounce in 2024.

Barrick Mining Corporation (B - Free Report) also saw a 9% sequential decline in AISC in the third quarter, reaching $1,538 per ounce. This downside was driven by lower total cash costs per ounce and lower minesite sustaining capital expenditures. Barrick maintained its cost guidance for the full year. For 2025, Barrick projects AISC in the range of $1,460-$1,560 per ounce, indicating a year-over-year increase at the midpoint.

The Zacks Rundown for AEMShares of Agnico Eagle have shot up 115.9% year to date against the Zacks Mining – Gold industry’s rise of 130.1%, largely driven by the gold price rally.

Image Source: Zacks Investment Research

From a valuation standpoint, AEM is currently trading at a forward 12-month earnings multiple of 19.51, a roughly 46.1% premium to the industry average of 13.35X. It carries a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for AEM’s 2025 and 2026 earnings implies a year-over-year rise of 82.3% and 20.7%, respectively. The EPS estimates for 2025 and 2026 have been trending higher over the past 60 days.

Image Source: Zacks Investment Research

Key Takeaways Kronos Worldwide reported a Q3 net loss of $37M versus a $71.8M profit in the prior year.Sales fell 6% to $456.9M, driven by weaker TiO2 prices and reduced European and export volumes.Kronos plans further inventory and cost cuts as it braces for softer Q4 and full-year results.
Kronos Worldwide, Inc. (KRO - Free Report) reported a third-quarter 2025 net loss of $37 million or 32 cents per share. This compares unfavorably to profits of $71.8 million, or 62 cents per share in the year-ago quarter.

Barring one-time items, adjusted loss came in at 18 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 6 cents.

Net sales decreased around 6% year over year to $456.9 million. The decline was mainly due to lower average titanium dioxide (TiO2) selling prices and reduced sales volumes in the company’s European and export markets, partly offset by higher sales volumes in the North American market. The top line missed the Zacks Consensus Estimate of $478.5 million.

KRO saw softer customer demand in the reported quarter, continuing the weakness that started earlier this year. High interest rates and economic uncertainties due to trade tensions and tariffs continued to contribute to cautious customer spending.

KRO’s Volumes and PricingTiO2 production volumes (thousand metric tons) were down roughly 11% year over year to 126 in the third quarter. TiO2 sales volumes (thousand metric tons) declined around 3% to 126 in the quarter.

TiO2 segment loss was $15.3 million in the reported quarter compared with a segment profit of $43.4 million a year ago. The downside was mainly due to reduced income from operations as a result of unfavorable fixed cost absorption stemming from reduced operating rates at certain of KRO’s manufacturing facilities and increased cost inventory produced in the second quarter relative to the year-ago quarter.

KRO’s FinancialsKronos ended the quarter with cash and cash equivalents of $27.7 million, up around 47% from the prior quarter. Long-term debt amounted to $626.2 million, up around 25% sequentially.

KRO’s OutlookThe company does not envision sales volumes to improve meaningfully in the near term. It is taking additional actions in the fourth quarter to reduce inventory levels through the reduction of operating rates to better align with current demand levels amid the subdued demand environment. KRO expects these actions to improve operating cash flows as it focuses on boosting liquidity to navigate through the current demand environment. The company is also implementing additional cost reduction initiatives to improve its cost structure.

Kronos anticipates operating results in the fourth quarter to be lower than the third quarter and also expects to report lower year-over-year operating results for full-year 2025, factoring in lower-than-expected demand, continued pricing pressure and lower fixed cost absorption due to reduced operating rates.

KRO’s Zacks Rank & Other Chemical ReleasesKRO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Chemours Company’s (CC - Free Report) third-quarter adjusted earnings were 20 cents per share, which missed the Zacks Consensus Estimate of 24 cents. Chemours expects fourth-quarter net sales to fall 10-15% sequentially due to seasonality.

Element Solutions Inc. (ESI - Free Report) logged third-quarter adjusted earnings per share of 41 cents per share, beating the Zacks Consensus Estimate of 39 cents. ESI anticipates full-year 2025 adjusted EBITDA in the range of $545 million to $550 million.

Huntsman Corporation’s (HUN - Free Report) adjusted loss per share was 3 cents compared with earnings of 10 cents in the year-ago quarter. It was narrower than the Zacks Consensus Estimate of a loss of 13 cents. HUN’s restructuring programs, which are expected to deliver more than $100 million in savings, remain on course and are expected to be completed this year.

Amaroq Ltd. (AMRQ:CA) Q3 2025 Earnings Call November 14, 2025 4:00 AM EST

Company Participants

Edward Westropp - Head of Business Development & Corporate Affairs
Eldur Olafsson - Founder, President, CEO & Director
Ellert Arnarson - Chief Financial Officer
Joan Plant

Presentation

Edward Westropp
Head of Business Development & Corporate Affairs

Good morning, everyone. Welcome to the Q3 2025 results from Amaroq. Thanks for joining. We'll follow the usual call for today. So management will take you through the presentation, and then we'll follow that with Q&A.

First of all, from the line, moderated by Sharon. And then I'll moderate the questions on the web.

So thanks very much for joining. I'll hand over to Eldur Olafsson, the Chief Executive.

Eldur Olafsson
Founder, President, CEO & Director

Thank you, Edward. Good morning, everybody. It's a pleasure to be with you here today after a very busy and successful quarter. I want to start the day up by giving you a snapshot of our operation as we usually do on this quarter. So we are very much focused on our mining development in Greenland, meaning now production, development and exploration. To do that, we are in Greenland. And as you can see, Greenland needs a lot of services and energy to enable these businesses to be successful. And therefore, out of necessity, we have set up this business as well.

We are mainly focused on 2 different regions in Greenland. We are in South Greenland, where you have Gold Belt, you have rare earth, non-rare earth areas and then you have copper and base metals. There, we have the Nalunaq mine. We have the Nanoq exploration development project, and then we have early-stage exploration in Vagar.

In West Greenland, there we have the Black Angel past producing mine, and the intention is to bring that into

Recommended For You

LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 5, 2025 to July 23, 2025

DEADLINE: December 2, 2025

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Molina admitted to a “dislocation between premium rates and medical cost trend;” that was likely to impact its financial guidance for fiscal year 2025. Based on these facts, Molina’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

Key Takeaways Walmart's vast omnichannel ecosystem and new higher-margin ventures underpin its growth outlook.
WMT posted Q2 sales up 5.6%, global e-commerce up 25%, and gains in advertising and membership income.
Target saw a 1.9% comp-sales drop but 4.3% digital growth, driven by expansion in same-day fulfillment.

Walmart Inc. (WMT - Free Report) and Target Corporation (TGT - Free Report) stand as two of the most recognized names in the U.S. retail industry. While they share similarities in scale and omnichannel ambitions, their business models and strategic focuses remain distinctly different.

Walmart’s foundation rests on unparalleled global scale and operational reach. The company operates more than 10,500 stores across 19 countries, spanning its flagship Walmart U.S. segment, Sam’s Club, and Walmart International. Its business model centers on “everyday low prices” — a value-driven approach that continues to attract a broad customer base across income levels. The company boasts a market capitalization of about $817 billion.

Target, with a market cap of $41.2 billion, operates nearly 2,000 stores across the United States, strategically positioned to serve as both retail destinations and fulfillment centers. Its model blends style and affordability, offering a curated mix of essentials, apparel, home goods and discretionary categories — all underpinned by a strong owned-brand portfolio that exceeds $30 billion in annual sales.

As consumers tighten spending amid tariff pressures and ongoing cost inflation, the question is: Which of these retail giants is better positioned to sustain growth?

The Case for WalmartWalmart has evolved far beyond its brick-and-mortar roots. It has built one of the largest omnichannel ecosystems in the world, using its store network as fulfillment hubs for pickup and same-day delivery. This integration of digital and physical assets has enhanced convenience while keeping last-mile costs competitive. E-commerce remains a key growth lever, supported by initiatives like Walmart Marketplace and its third-party fulfillment services.

Complementing its retail strength are newer, higher-margin businesses such as Walmart Connect (advertising), Walmart+ (membership) and financial services offerings. These ventures are transforming Walmart’s profit profile, helping diversify earnings beyond merchandise sales. Its membership base also strengthens customer loyalty and recurring income streams, reinforcing the company’s ecosystem advantage.

Technology and automation continue to be central to Walmart’s long-term strategy. From AI-driven inventory systems to supply-chain digitization and advanced analytics, Walmart’s investments aim to enhance productivity, improve in-stocks and preserve its price leadership despite tariff-related cost pressures. The company’s international operations, including growth markets like Mexico, China, and India (Flipkart), provide additional expansion avenues and geographic diversification.

In the second quarter of fiscal 2026, Walmart’s consolidated sales rose 5.6% at constant currency, with global e-commerce up 25%. Advertising revenues soared 46% globally (with Walmart Connect up 31%), while membership income grew 15% in the quarter, led by Walmart+ and Sam’s Club Plus tiers.

However, Walmart faces persistent challenges, including higher goods costs due to tariffs, rising claims expenses, and moderation in discretionary spending among middle- and lower-income households. Yet, with a diversified model, strong balance sheet, and growing share in e-commerce and advertising, the company appears well-equipped to manage these pressures.

The Case for TGTTarget’s strength lies in merchandising and brand experience. Its stores are designed to inspire discovery, appealing to shoppers who value convenience but also seek design and quality. The company’s private-label brands — such as Cat & Jack, Good & Gather and Threshold — reinforce its differentiation and provide margin stability. Target also partners with major brands to enhance in-store excitement and exclusivity.

Digitally, Target has built a highly efficient fulfillment engine that integrates online and store-based operations. Services like Drive Up, Order Pickup and same-day delivery through Target Circle 360 (its expanded loyalty and membership ecosystem) have become critical components of its omnichannel strategy. These offerings leverage its store base to lower delivery costs and sustain traffic even as online sales grow.

In the second quarter of fiscal 2025, comparable sales declined 1.9%, marking a notable sequential improvement from the prior quarter’s steeper drop. However, digital sales went up 4.3%, fueled by strong demand for same-day fulfillment, which rose more than 25%.

Strategically, Target is focused on improving efficiency, accelerating technology adoption, and enhancing product freshness and availability. Investments in AI-based forecasting, inventory automation, and supply-chain modernization aim to improve execution and speed. Initiatives like “Fun 101” — which refresh product assortments with trend-led innovation — demonstrate Target’s effort to reclaim its merchandising leadership.

Still, Target faces near-term headwinds. Its discretionary-heavy mix makes it more exposed to fluctuations in consumer sentiment. Tariff-related cost pressures, competitive pricing dynamics, and higher promotional intensity also weigh on margins. However, the company’s brand equity, loyal customer base and strong store network provide a sturdy platform for recovery once macro conditions stabilize.

How Does the Zacks Consensus Estimate Compare for WMT & TGT?The Zacks Consensus Estimate for Walmart’s current fiscal-year sales and EPS suggests a year-over-year increase of nearly 4% each. The consensus estimate for EPS for the current fiscal year has increased by a penny to $2.61 over the past 60 days.
 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Target’s current fiscal-year sales and EPS implies year-over-year declines of 1.4% and 16.6%, respectively. The consensus estimate for EPS for the current fiscal year has declined from $7.45 to $7.39 over the past 60 days.

Image Source: Zacks Investment Research

WMT & TGT: A Look at Past-Year Stock PerformanceOver the past year, shares of Walmart have gained 21.7%, while Target has slumped 40.4%. Based on recent performance, Walmart appears to be the stronger pick.

Image Source: Zacks Investment Research

WMT vs. TGT: A Peek Into Stock ValuationWalmart’s forward P/E of 35.88 sits above its median of 35.67. Target is trading at a forward 12-month price-to-earnings (P/E) ratio of 11.4, below its one-year median of 12.44. On valuation grounds, Target looks better, as its forward P/E is below its historical median, signaling relative undervaluation compared to Walmart’s premium multiple above its median.

Image Source: Zacks Investment Research

WMT vs. TGT: Which Is the Better Bet Now?Walmart and Target remain integral forces in U.S. retail, yet their paths forward differ meaningfully. Walmart’s unmatched scale, strong e-commerce growth, and expanding profit engines in advertising and membership provide stability and consistent earnings visibility. Meanwhile, Target retains a powerful brand identity and an improving digital and supply-chain foundation, but near-term growth is constrained by discretionary weakness and margin pressure. While Target offers valuation appeal, Walmart currently stands as the stronger contender, backed by diversified growth drivers, global reach and proven operational resilience.

WMT and TGT each carry a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Resources

Investor Relations

Journalists

Agencies

Client Login

Send a Release

News

Products

Contact

Financial Statements for Q3 2025

, /PRNewswire/ -- Elah Holdings, Inc. (OTC:ELLH) announces that it has released its interim unaudited financial statements and disclosure report for the third quarter of 2025. This report and additional company information can be found at www.elahholdings.com under the Financial Releases section of the website.

About Elah Holdings

Elah Holdings, Inc. (formerly known as Real Industry, Inc.) is a holding company led by experienced business leaders that is seeking to acquire profitable businesses in the commercial and industrial markets to generate sustainable profitability and cash flows, unlock the value of our considerable tax assets, and use creative deal structures that reduce risk and ultimately create long-term value for our shareholders. For more information, visit www.elahholdings.com. Elah Holdings' stock trades on the OTC Pink Market, which is operated by OTC Markets Group, a centralized electronic quotation service for over-the-counter securities under the symbol "ELLH."

Contact:

Michael Hobey

Elah Holdings, Inc.
+1 (805) 435-1255

@elah_inc

www.linkedin.com/company/elah-holdings-inc/

SOURCE Elah Holdings, Inc.

Also from this source

Key Takeaways KOD's Q3 loss widened to $1.16 per share as R&D costs rose on increased clinical and manufacturing activity.KOD is advancing tarcocimab and KSI-501 in phase III DR and wet AMD studies with data expected in 2026.KOD's phase III PEAK and PINNACLE studies for KSI-101 are currently enrolling macular edema patients.
Kodiak Sciences (KOD - Free Report) reported a loss of $1.16 per share in the third quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.07. The company had incurred a loss of 84 cents per share in the year-ago quarter.

The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.

KOD's Q3 Results in DetailResearch and development expenses were $50.5 million in the reported quarter, up 58% year over year. The improvement was mainly due to increased clinical and manufacturing activities associated with ongoing clinical studies.

General and administrative expenses were $11.9 million, down 20% year over year, primarily due to lower non-cash stock-based compensation expenses.

As of Sept. 30, 2025, Kodiak had cash, cash equivalents and marketable securities worth $72 million compared with $104.2 million as of June 30, 2025.

Shares of Kodiak have surged 89.1% year to date compared with the industry’s 15.4% growth.

Image Source: Zacks Investment Research

KOD's Key Pipeline UpdatesKodiak is evaluating the efficacy and safety of tarcocimab in treatment-naïve patients with diabetic retinopathy (DR) in the phase III GLOW2 study. Top-line data is expected in the first quarter of 2026.

KOD’s second clinical candidate, KSI-501, a dual inhibitor Trap-Antibody-Fusion bioconjugate molecule, is designed to target concurrent inflammation and abnormal angiogenesis observed in the pathogenesis of retinal vascular diseases.

The company is also studying tarcocimab as a second investigational arm in the phase III DAYBREAK study to treat wet age-related macular degeneration (wet AMD), with KSI-501 being the first investigational arm. Top-line data from both arms of the DAYBREAK study are anticipated in the third quarter of 2026.

Based on the success of these two pivotal studies, Kodiak plans to submit a single regulatory filing, seeking the approval of tarcocimab for three large indications — DR, wet AMD and retinal vein occlusion.

Kodiak has also completed an early-stage study evaluating its third investigational candidate, KSI-101, for macular edema. The candidate is a novel, potent, high-strength bispecific protein targeting IL-6 and VEGF. Following its success, KOD has initiated two pivotal phase III studies (PEAK and PINNACLE) investigating two dose levels (5 mg and 10 mg) of KSI-101 for macular edema secondary to inflammation. Both studies are currently enrolling patients with top-line results expected in late 2026 and early 2027, respectively.

KOD's Zacks Rank & Stocks to ConsiderKodiak currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , Arcutis Biotherapeutics (ARQT - Free Report) and ADMA Biologics (ADMA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 52.8%.

ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 21.24%.

In the past 60 days, estimates for Arcutis Biotherapeutics’ loss per share have narrowed from 44 cents to 24 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 9 cents to 41 cents. Year to date, shares of ARQT have rallied 64.1%.

Arcutis Biotherapeutics’ earnings beat estimates in each of the trailing four quarters, the average surprise being 64.80%.

In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 57 cents to 58 cents for 2025. During the same time, earnings per share estimates for 2026 have improved from 88 cents to 90 cents. Year to date, shares of ADMA have lost 8.4%.

ADMA Biologics’ earnings beat estimates in one of the trailing four quarters, matched once and missed the same on the remaining two occasions, with the average negative surprise being 3.01%.

NVIDIA (NVDA) has faced challenges in the past. Its stock has dropped over 30% within less than 2 months on 8 occasions in various years, erasing billions in market value and eliminating substantial gains in a single correction. If past performance is any indicator, NVIDIA (NVDA) stock is not shielded from abrupt, steep declines.

SAN JOSE, CALIFORNIA - MARCH 18: Nvidia CEO Jensen Huang delivers the keynote address during the Nvidia GTC 2025 at SAP Center on March 18, 2025 in San Jose, California. The annual Nvidia GTC conference runs through March 20th. (Photo by Justin Sullivan/Getty Images)

Getty Images

Although NVIDIA’s stock has skyrocketed due to the unwavering demand for its AI hardware, elevating its market valuation to record levels, this very momentum also introduces new risks. The relentless demand for AI chips has sparked increased competition from rivals and even its top cloud clients who are designing their own proprietary silicon, while ongoing geopolitical issues highlight the fragility of its vital supply chains, suggesting that even with market leadership, there can be underlying uncertainties.

What Could Cause The Stock To Plunge?

China Market Decline: U.S. export restrictions and rising domestic competition from companies like Huawei are expected to decrease NVIDIA’s AI chip market share in China, which would affect a substantial market opportunity.Custom AI Chips: Major hyperscalers (Google, Amazon, Meta) are increasingly creating their own custom AI chips, including Google’s Ironwood TPUs, to lower dependence on NVIDIA and optimize for particular workloads, especially in the rapidly growing inference sector.Competitor Chip Advancement: AMD’s Instinct MI300X series, with the MI350X, along with Intel’s Gaudi 3, are gaining traction in AI accelerators. AMD recently provided a long-term outlook, noting that it expects revenue growth to average over 35% over the next three to five years, with AI data center revenue rising by an average of 80% over the same period.
Are Risks Apparent In The Financials Yet?

Let's examine the fundamentals.

Revenue Growth: 71.6% LTM and 92.0% over the last 3-year average.Cash Generation: Approximately 43.6% free cash flow margin and 58.1% operating margin LTM.Valuation: NVIDIA stock currently has a P/E ratio of 52.6.NVDA

Trefis

If you're seeking more information, read Buy or Sell NVDA Stock. However, consider this question – Is holding NVDA stock risky? Absolutely it is. High Quality Portfolio can help mitigate that risk.

MORE FOR YOU

What’s The Worst That Could Occur?

A review of NVIDIA’s performance during market downturns indicates that significant risks remain despite its strengths. The stock experienced a decline of approximately 85% during the Global Financial Crisis and 68% during the Dot-Com crash. The sell-off in 2018 and the inflation shock both witnessed drops exceeding 55%, with the latter around 66%. Even the Covid dip, which was relatively short-lived, caused the stock to drop nearly 38%. Strong fundamentals are important, but when the market shifts, NVDA is not immune to rapid declines.

However, risks are not confined to significant market crashes. Stocks can fall even in good market conditions – considering events such as earnings releases, business updates, and changes in outlook. Review NVDA Dip Buyer Analyses to see how the stock has bounced back from sharp declines previously.

The Trefis High Quality (HQ) Portfolio, comprised of 30 stocks, has established a track record of consistently beating its benchmark, which includes all three – the S&P 500, S&P mid-cap, and Russell 2000 indices. What accounts for this? Together, HQ Portfolio stocks have yielded higher returns with lower risk compared to the benchmark index; they experience less volatility, as shown in the HQ Portfolio performance metrics.

November 14, 2025 7:30 AM EST | Source: Atlas Lithium Corporation
Boca Raton, Florida--(Newsfile Corp. - November 14, 2025) - Atlas Lithium Corporation (NASDAQ: ATLX) ("Atlas Lithium" or "Company"), a leading lithium development company advancing Brazil's premier hard-rock lithium project, yesterday filed its quarterly financial statements with the Securities and Exchange Commission ("SEC"), demonstrating robust financial strength and significant momentum in procurement activities for its flagship Neves Project.

Strong Financial Foundation Supports Project Advancement

The Company's presented financial results underscore a solid financial position. In particular, the Company demonstrated a robust liquidity profile with cash and cash equivalents of $20.98 million as of September 30, 2025, representing 89% of its current assets of $23.55 million. With current liabilities of $6.38 million, Atlas Lithium maintains a strong current ratio of 3.69, highlighting financial strength. The Company's working capital of $17.17 million provides ample flexibility to meet current obligations, and fund ongoing operations without reliance on external financing.

"Our robust cash position and minimal debt provide us with the financial foundation to execute our development strategy while maintaining operational flexibility," said Marc Fogassa, Chairman and CEO of Atlas Lithium. "Our balance sheet is stronger than ever, a key factor in a market where lithium prices are still recovering."

Procurement Activities Demonstrate Strong Industry Interest

Atlas Lithium is making steady and substantial progress in its procurement processes, with strong interest from suppliers eager to participate in the Company's Neves Project implementation. The Company has attracted a broad group of bidders across multiple procurement packages to maximize opportunities for securing the most competitive solutions while allowing suppliers flexibility to propose alternative solutions. Key procurement milestones include:

Multiple Technical Site Visits: Atlas Lithium successfully hosted four comprehensive technical site visits in September 2025, with strong attendance from qualified contractors:September 9-10: Earthworks - 17 companies participated

September 11: Administrative & Operational Buildings - 14 companies attended

September 15: Civil Works - 11 companies engaged

September 16: Mechanical Assembly - 12 companies participated

Extensive Supplier Engagement: The Company received and processed 2,813 clarification questions from potential suppliers across all procurement packages, demonstrating exceptional market interest in the projectCritical Procurement Packages Advancing: Other key processes representing approximately 70% of the project's estimated direct capital expenditures are also advancing, including: Electromechanical Assembly

Mine Operation & Pre-Stripping

Crushing Equipment

Internal Road Engineering

"The exceptional level of contractor interest that we have witnessed appears to validate the attractiveness of our Neves Project," commented Eduardo Queiroz, PMO and VP of Engineering at Atlas Lithium. "With multiple qualified bidders competing across all major work packages, we are confident in our ability to secure competitive pricing and high-quality execution partners."

Strategic Progress Toward Production

The procurement activities are advancing in parallel with other critical project development workstreams as Atlas Lithium progresses toward its target of commencing production. The Company's Definitive Feasibility Study (DFS), completed by SGS Canada Inc. in August 2025, demonstrates robust project economics that position Atlas Lithium very well and among the world's most capital-efficient lithium developers. The DFS highlights robust financial metric estimates including a 145% after-tax Internal Rate of Return, $539 million after-tax Net Present Value, 11-month payback period, and operating costs of $489 per tonne of lithium concentrate. With projected direct capital expenditure of only $57.6 million - the lowest among announced projects in Brazil - the Neves Project benefits from open-pit mining with spodumene located near the surface and high-quality, low-impurity material as primary drivers of reduced costs. With the key operational permits secured in October 2024 and the $30M modular DMS processing plant now ready for assembly in Brazil, the Company continues to execute and steadily advance on its strategy to become a supplier of premium-quality lithium concentrate to global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based upon the current plans, estimates and projections of Atlas Lithium and its subsidiaries and are subject to inherent risks and uncertainties which could cause actual results to differ from the forward-looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; any projections of production, reserves, sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; uncertainties related to conducting business in Brazil, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. Therefore, you should not place undue reliance on these forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Atlas Lithium's ability to successfully assemble and begin operations of its modular plant; reaching estimated production, development plans and cost estimates for the Neves Lithium Project as reported in the Definitive Feasibility Study (the "DFS"); discrepancies between actual and estimated mineral reserves and mineral resources, between actual and estimated development and operating costs, and between estimated and actual production; results from ongoing geotechnical analysis of projects; business conditions in Brazil; general economic conditions, geopolitical events, and regulatory changes; availability of capital; Atlas Lithium's ability to maintain its competitive position; manipulative attempts by short sellers to drive down our stock price; and dependence on key management.

Additional risks related to the Company and its subsidiaries are more fully discussed in the section entitled "Risk Factors" in the Company's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025, and in the Company's Form 10-Q filed with the SEC on November 13, 2025. Please also refer to the Company's other filings with the SEC, all of which are available at www.sec.gov. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274484

- Acquired 11 MW site in Mississippi with 7.5 MW mining in September and 26 MW total power capacity
- Raised net $21.3 million in August to build Bitcoin Treasury
- Mining margin improved to 49.0% from 41.0% in Q2 2025
- Executed private repurchase in October and authorized share buyback
- As of October 31, 2025 held 294.9 Bitcoin valued at approximately $32.2 million

TAMPA, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today reported financial results for the three months ended September 30, 2025.

Q3’25 Financial Highlights

Total revenue for the quarter was $2.2 million dollars, up 13.0% sequentially from Q2 2025 and 73.5% year-over-year. The increase was driven by higher average Bitcoin prices and contributions from the Mississippi facility for the second half of September.The Company mined 17.6 Bitcoins during the quarter at an average price of approximately $114,000, compared to 18.4 Bitcoins in Q2 2025 at an average price of approximately $98,000. The sequential decline was due to higher curtailment and increased difficulty rate.Mining margin improved to 49.0%, compared with 41.0% in the second quarter 2025, driven by eliminating hosting costs, curtailment and energy sales offsetting mining costs, and higher fleet efficiency. The Company generated approximately $152,000 in curtailment and energy sales for the quarter. Mining margin is calculated as digital mining revenues minus digital mining cost of revenues net of curtailment and energy sales.Operating expenses increased $0.4 million driven by increase in staff costs related to the Mississippi site acquisition and performance compensation bonuses offset in part by gain on fair value of Bitcoin totaling $1.0 million.Net loss for the quarter was $3.7 million and Core EBITDA1 loss was $1.4 million as compared to the prior year quarter Net loss of $4.3 million and Core EBITDA loss of $1.9 million.Cash was approximately $0.3 million, and Bitcoin holdings totaled 304.5 Bitcoin, valued at $34.7 million based on Bitcoin price of approximately $114,000, as of September 30, 2025.Net book value of LM Funding stockholders’ equity was approximately $50.1 million, or $3.23 per share2, as of September 30, 2025.As of October 31, 2025 the Company held 294.9 Bitcoin, valued at approximately $32.2 million, based on a Bitcoin price of $109,225 as of October 31, 2025, or $2.64 Bitcoin per share3. Q3’25 and Recent Operational Highlights

$21.3 Million Treasury Raise: During the third quarter, LM Funding successfully raised approximately net $21.3 million through a $12.6 million registered direct offering and a $10.4 million private placement in August 2025, with the net proceeds primarily dedicated to enhancing the Company’s Bitcoin treasury. Proceeds from the financings were deployed to acquire 164 Bitcoin, increasing the Company’s holdings to approximately 304.5 Bitcoin as of quarter-end, further strengthening LM Funding’s balance sheet and long-term position.Mississippi 11 MW Acquisition: During the third quarter, LM Funding acquired an 11 MW Bitcoin mining facility in Columbus, Mississippi, advancing the Company’s vertical integration strategy. Approximately 7.5 MW of capacity were energized at closing, enabling immediate contribution to production. In addition, LM Funding redeployed more efficient miners to the site to optimize uptime and fleet performance. As a result, the Company achieved a 27.8% increase in Bitcoin production in October 2025 compared to September 2025.Oklahoma 2 MW Expansion: The Company made meaningful progress on its 2 MW immersion expansion at its 15 MW site in Oklahoma and secured 320 Bitmain S21 immersion units to support the upgrade. Containerized immersion systems are scheduled to be delivered this month, with energization targeted for December 2025, positioning the site to benefit from improved thermal performance, higher efficiency, and more consistent uptime year-round.Share Repurchase and Authorized Buyback Program: The Company recently completed a privately negotiated repurchase of approximately 3.3 million shares and warrants to purchase 7.3 million common shares that were originally issued in its August 2025 private placement, for a total purchase price of approximately $8.0 million. The transaction was financed through an $11 million credit facility with Galaxy Digital. Following the private repurchase, the Company’s Board of Directors authorized a $1.5 million share buyback program. Together, these actions reflect LM Funding’s conviction in its intrinsic value and commitment to increasing Bitcoin per share and mNAV for shareholders. Management Commentary

“The third quarter was about execution, integration, and disciplined capital allocation,” said Bruce Rodgers, Chairman and CEO of LM Funding. “We strengthened our Bitcoin treasury through a $21.3 million financing, completed the acquisition and integration of a 11-megawatt Mississippi facility, and expanded our owned infrastructure to 26 megawatts across two sites. After quarter-end, we simplified our capital structure with a private repurchase of units and authorized a share buyback program — tangible actions that demonstrate our belief in the value we’re building. We are long on Bitcoin and confident in our strategy to build equity value, and every decision we make is focused on improving per-share intrinsic value over time.”

“From closing and integrating the Mississippi facility to optimizing fleet performance and achieving a 28% month-over-month increase in Bitcoin production in October, we saw the benefits of control and scale take hold these last four months,” said Ryan Duran, President of US Digital Mining (“USDM”). “We now operate roughly 0.71 EH/s of capacity across 26 megawatts, with the next efficiency leap coming as our 2 MW immersion expansion in Oklahoma is anticipated to energize in December. The foundation continues to be built — owned power, efficient machines, and operational flexibility — and our focus from here is improving production, efficiency, and Bitcoin per share.”

“Revenue increased 74% year-over-year, mining margins improved to 49%, and our corporate actions are aimed at materially enhancing per-share value,” said Richard Russell, CFO of LM Funding. “Following quarter-end, we deployed $8.0 million from our Galaxy loan facility to repurchase more than 3.3 million shares and 7.3 million warrants, removing dilution and reducing share count. With a $1.5 million authorized buyback in place and a balance sheet anchored by Bitcoin, we have the flexibility to fund operations, expand capacity, and increase shareholder value while growing our Bitcoin treasury.”

Investor Conference Call

LM Funding America, Inc. (Nasdaq: LMFA) operates as a Bitcoin treasury and mining company. The Company was founded in 2008 and is based in Tampa, Florida. The Company also operates a technology-enabled specialty finance business that provides funding to nonprofit community associations primarily in the State of Florida. For more information, please visit https://www.lmfunding.com.

Conference Call Details

Date: November 14, 2025 Time: 8:00 AM EST Participant Call Links:  Live Webcast: Link Participant Call Registration: Link 
Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the Company's most recent Annual Report on Form 10-K and its other filings with the SEC, which are available at www.sec.gov. These risks and uncertainties include, without limitation, the risks of operating in the cryptocurrency mining business, our limited operating history in the cryptocurrency mining business and our ability to grow that business, the capacity of our Bitcoin mining machines and our related ability to purchase power at reasonable prices, our ability to identify and acquire additional mining sites, the ability to finance our site acquisitions and cryptocurrency mining operations, the risks associated with growing our Bitcoin treasury operations and strategy, our ability to acquire new accounts in our specialty finance business at appropriate prices, changes in governmental regulations that affect our ability to collected sufficient amounts on defaulted consumer receivables, changes in the credit or capital markets, changes in interest rates, and negative press regarding the debt collection industry. The occurrence of any of these risks and uncertainties could have a material adverse effect on our business, financial condition, and results of operations.

For investor and media inquiries, please contact:

Investor Relations
Orange Group
Yujia Zhai
[email protected]

    LM Funding America, Inc. and Subsidiaries Unaudited Consolidated Balance Sheets
     September 30, December 31, 2025
(unaudited) 2024
Assets   Cash$291,571  $3,378,152 Digital assets - current (Note 3) 11,399,701   9,021,927 Finance receivables 28,148   21,051 Marketable securities (Note 6) 23,630   27,050 Receivable from sale of Symbiont assets (Note 6) -   200,000 Prepaid expenses and other assets 904,079   827,237 Digital assets - collateral (Note 3) 5,500,000   - Income tax receivable 31,187   31,187 Current assets 18,178,316   13,506,604     Fixed assets, net (Note 4) 15,655,533   18,376,948 Intangible assets, net (Note 4) 6,748,137   5,478,958 Deposits on mining equipment (Note 5) 501,228   467,172 Long-term investments - equity securities (Note 6) 5,598   4,255 Investment in Seastar Medical Holding Corporation (Note 6) 58,995   200,790 Digital assets - long-term (Note 3) 16,402,955   - Digital assets - collateral (Note 3) 1,430,000   5,000,000 Right of use assets (Note 8) 785,918   938,641 Other assets 389,119   73,857 Long-term assets 41,977,483   30,540,621 Total assets$60,155,799  $44,047,225     Liabilities and stockholders' equity   Accounts payable and accrued expenses 3,071,168   989,563 Note payable - short-term (Note 7) 6,579,828   386,312 Due to related parties (Note 10) 59,337   15,944 Current portion of lease liability (Note 8) 190,821   170,967 Total current liabilities 9,901,154   1,562,786     Note payable - long-term (Note 7) 1,243,397   6,365,345 Lease liability - net of current portion (Note 8) 605,234   776,535 Long-term liabilities 1,848,631   7,141,880 Total liabilities 11,749,785   8,704,666     Stockholders' equity (Note 9)   Preferred stock, par value $.001; 150,000,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 -   - Common stock, par value $.001; 350,000,000 shares authorized; 15,517,988 and 5,133,412 shares issued and outstanding as of September 30, 2025 and December 31, 2024 14,987   4,602 Additional paid-in capital 124,810,596   102,685,470 Accumulated deficit (74,690,296)  (65,662,731)Total LM Funding America stockholders' equity 50,135,287   37,027,341 Non-controlling interest (1,729,273)  (1,684,782)Total stockholders' equity 48,406,014   35,342,559 Total liabilities and stockholders’ equity$60,155,799  $44,047,225      LM Funding America, Inc. and Subsidiaries Unaudited Consolidated Statements of Operations
     Three Months ended September 30, Nine Months ended September 30, 2025
 2024
 2025
 2024
Revenues:       Digital mining revenues$2,010,404  $1,127,455  $6,090,708  $8,618,436 Specialty finance revenue 141,634   97,558   303,968   303,222 Rental revenue 26,265   30,460   83,288   92,766 Total revenues 2,178,303   1,255,473   6,477,964   9,014,424 Operating costs and expenses:       Digital mining cost of revenues (exclusive of depreciation and amortization shown below) 1,177,184   730,716   4,013,878   5,742,773 Curtailment and energy sales (151,887)  -   (524,842)  - Staff costs and payroll 2,537,105   1,567,984   4,675,209   3,648,898 Depreciation and amortization 1,972,133   1,935,835   6,049,054   5,787,390 Gain on fair value of Bitcoin, net (1,032,374)  (104,744)  (2,983,537)  (3,096,774)Impairment loss on mining equipment -   -   -   1,188,058 Professional fees 443,335   628,686   1,116,649   1,622,914 Selling, general and administrative 448,487   209,088   1,133,871   582,675 Real estate management and disposal 14,687   31,144   73,421   89,430 Collection costs 1,702   15,054   27,643   36,396 Settlement costs with associations -   -   3,693   - Loss on disposal of assets -   12,449   286,359   54,506 Other operating costs 284,929   229,784   799,889   667,401 Total operating costs and expenses 5,695,301   5,255,996   14,671,287   16,323,667 Operating loss (3,516,998)  (4,000,523)  (8,193,323)  (7,309,243)Unrealized gain (loss) on marketable securities 10,400   (3,296)  (3,420)  984 Impairment loss on prepaid machine deposits -   (12,941)  -   (12,941)Unrealized gain (loss) on investment and equity securities 16,422   (346,866)  (140,452)  (852,624)Gain (loss) on fair value of purchased Bitcoin, net -   -   (52,704)  57,926 Other income - coupon sales -   -   -   4,490 Interest expense (235,282)  (124,035)  (683,734)  (231,754)Interest income 916   98,343   2,592   124,696 Loss before income taxes (3,724,542)  (4,389,318)  (9,071,041)  (8,218,466)Income tax expense -   -   -   - Net loss$(3,724,542) $(4,389,318) $(9,071,041) $(8,218,466)Less: loss (gain) attributable to non-controlling interest (4,903)  105,043   43,476   265,296 Net loss attributable to LM Funding America Inc.$(3,729,445) $(4,284,275) $(9,027,565) $(7,953,170)Less: deemed dividends (Note 9) (347,782)  (1,704,305)  (347,782)  (1,704,305)Net loss attributable to common shareholders$(4,077,227) $(5,988,580) $(9,375,347) $(9,657,475)        Basic loss per common share (Note 1)$(0.41) $(2.25) $(1.39) $(3.82)Diluted loss per common share (Note 1)$(0.41) $(2.25) $(1.39) $(3.82)        Weighted average number of common shares outstanding       Basic 9,986,433   2,659,974   6,768,862   2,525,160 Diluted 9,986,433   2,659,974   6,768,862   2,525,160                  LM Funding America, Inc. and Subsidiaries Unaudited Consolidated Statements of Cash Flows
   Nine Months ended September 30, 2025
 2024
CASH FLOWS FROM OPERATING ACTIVITIES:   Net loss$(9,071,041) $(8,218,466)Adjustments to reconcile net loss to net cash used in operating activities       Depreciation and amortization 6,049,054   5,787,390 Noncash lease expense 152,723   79,629 Amortization of debt issue costs 66,994   - Stock issued for services -   100,001 Stock compensation -   76,322 Stock option expense 259,384   332,415 Accrued investment income -   (123,076)Accrued interest expense on finance lease 42,875   - Digital assets other income -   (4,490)Gain on fair value of Bitcoin, net (2,930,833)  (3,154,700)Impairment loss on mining machines -   1,188,058 Impairment loss on hosting deposits -   12,941 Unrealized loss (gain) on marketable securities 3,420   (984)Unrealized loss on investment and equity securities 140,452   852,624 Loss on disposal of fixed assets 286,359   54,506 Change in operating assets and liabilities:   Prepaid expenses and other assets 391,857   3,650,696 Repayments to related party 43,393   41,541 Accounts payable and accrued expenses 2,081,605   (664,681)Mining of digital assets (6,090,708)  (8,618,436)Lease liability payments (194,322)  (81,304)Net cash used in operating activities (8,768,788)  (8,690,014)CASH FLOWS FROM INVESTING ACTIVITIES:   Net collections of finance receivables - original product (3,145)  (4,618)Net collections of finance receivables - special product (3,952)  (1,571)Capital expenditures (635,691)  (1,228,428)Proceeds from sale of fixed assets 953,153   78,806 Collection of note receivable 200,000   1,449,066 Acquisition of hosting site (4,230,368)  - Investment in notes receivable -   (2,867,195)Investment in digital assets - Bitcoin (18,673,167)  - Investment in digital assets - Tether (29,572)  - Proceeds from sale of Bitcoin 6,984,091   6,821,185 Proceeds from the sale of Tether 29,460   3,003 Deposits for mining equipment (1,004,326)  - Distribution to members (1,015)  (19,616)Net cash provided by (used in) investing activities (16,414,532)  4,230,632 CASH FLOWS FROM FINANCING ACTIVITIES:   Proceeds from borrowings, net of issuance costs 1,240,195   6,344,084 Insurance financing repayments (588,123)  (547,022)Exercise of options -   25,000 Proceeds from warrant exercise 95,999   - Proceeds from the issuance of common stock, net of issuance costs 21,348,668   2,148,704 Net cash provided by financing activities 22,096,739   7,970,766 NET INCREASE (DECREASE) IN CASH (3,086,581)  3,511,384 CASH - BEGINNING OF PERIOD 3,378,152   2,401,831 CASH - END OF PERIOD$ 291,571   $   5,913,215          SUPPLEMENTAL DISCLOSURES OF NON-CASH ACTIVITIES       Insurance financing$352,501  $- Change in accounting principle (see Note 1)$-  $614,106 Issuance of common stock as retainer for services$431,460  $- SUPPLEMENTAL DISCLOSURES OF CASHFLOW INFORMATION   Cash paid for taxes$-  $- Cash paid for interest$489,083  $222,697          NON-GAAP CORE EBITDA RECONCILIATION

Our reported results are presented in accordance with U.S. generally accepted accounting principles (“GAAP”). We also disclose Earnings before Interest, Tax, Depreciation and Amortization ("EBITDA") and Core Earnings before Interest, Tax, Depreciation and Amortization ("Core EBITDA") which adjusts for unrealized loss (gain) on investment and equity securities, loss on disposal of mining equipment, impairment loss on mining equipment and stock compensation expense and option expense, all of which are non-GAAP financial measures. We believe these non-GAAP financial measures are useful to investors because they are widely accepted industry measures used by analysts and investors to compare the operating performance of Bitcoin miners.

The following tables reconcile net loss, which we believe is the most comparable GAAP measure, to EBITDA and Core EBITDA:

             Three Months ended September 30,
 Nine Months ended September 30,
 2025 2024 2025 2024        Net income (loss)$(3,724,542)  $(4,389,318)  $(9,071,041)  $(8,218,466) Income tax expense-  -  -  - Interest expense235,282  124,035  683,734  231,754 Depreciation and amortization1,972,133  1,935,835  6,049,054  5,787,390 Loss before interest, taxes & depreciation$(1,517,127)  $(2,329,448)  $(2,338,253)  $(2,199,322) Unrealized loss (gain) on investment and equity securities(16,422)  346,866  140,452  852,624 Loss on disposal of mining equipment-  12,449  286,359  54,506 Impairment loss on mining equipment-  -  -  1,188,058 Stock compensation and option expense123,958  110,806  259,384  408,737 Core income (loss) before interest, taxes & depreciation$(1,409,591)  $(1,859,327)  $(1,652,058)  $304,603          __________________________
1 Core EBITDA is a non-GAAP financial measure, and a reconciliation of Core EBITDA to net income can be found below.
2 Calculated using 15,517,988 shares outstanding as of September 30,2025.
3 Calculated using 12,209,413 shares outstanding as of October 31, 2025.

A buildup of U.S. military forces in the Caribbean Sea are raising concerns about a potential strike on Venezuela, which is home to the world's largest oil reserves.

Hydroponic Basil, Potted Herbs, and Wheatgrass Accelerate; International Nutraceutical Sales Nearly Double Year-Over-Year

Company's Portfolio Optimization and Expansion into CEA-Informed, Better-For-You Shelf Stable Categories Pushes Market Penetration and Growth

Conference Call to Be Held Today at 8:00 am ET.

BELVIDERE, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced financial results for the third quarter ended September 30, 2025. The third quarter is traditionally the slowest of the year for Edible Garden, however the results reflect the early benefits of the Company’s strategic evolution toward a CEA informed consumer packaged goods (CPG) model. The Company demonstrated revenue growth, with sales up 9% compared to the third quarter of 2024. Edible Garden also broadened its distribution network and gained momentum in the shelf-stable product segment. The fourth quarter, historically the Company’s strongest period, is expected to further demonstrate the positive impact of this transformation.

Financial & Operating Highlights for the Three Months Ended September 30, 2025

Non-perishable unit sales increased approximately 49.3% year-over-year, driven by strong performance across the Company’s shelf-stable product lines including Kick. Sports Nutrition, Pickle Party™, Pulp®, and Vitamin Whey®.Private Label products sold through major big box retailers outperformed in the second quarter, climbing 15.1% year-over-yearSame store Hydroponic Basil up 28.6%, Potted Herbs up 22.6%, and Wheatgrass up 59.2%International vitamin and supplements revenue rose 90.2% versus year-over-year “Over the past several quarters, we’ve been executing a strategic transformation of Edible Garden into a diversified, innovation-driven consumer packaged goods company, and we’re now seeing clear results,” said Jim Kras, Chief Executive Officer of Edible Garden. “The third quarter marked a key milestone as we experienced revenue growth, expanded our product distribution to Kroger to include fresh potted and cut herbs, added major retail customers including The Fresh Market, and expanded internationally through partners such as PriceSmart and Amazon.”

“Our CPG- focused strategy enables us to expand beyond fresh produce into shelf-stable, branded offerings that align with growing demand for clean-label, functional, and better-for-you foods. Our expanding portfolio - featuring Kick. Sports Nutrition, Pickle Party™, Pulp®, and Vitamin Whey® - is driving continued momentum and is expected to contribute to margin improvement, while supporting broader geographic reach and more consistent, year-round sales across both fresh and shelf-stable categories.”

“We further expanded our retail footprint during the quarter, launching our USDA Organic fresh herb line at Kroger, introducing Edible Garden-branded herbs at The Fresh Market, and strengthening our Midwest presence through Pete’s Fresh Market and Angelo Caputo’s Fresh Markets. We believe these relationships, along with robust private-label programs, underscore the growing strength of the Edible Garden brand and our commitment to freshness, innovation, and sustainability.”

“The acquisition of NaturalShrimp’s assets is expected to enhance our vertical integration and add sustainable aquaculture capabilities that align with our mission and brand values. Together with ongoing innovation under our Zero-Waste Inspired® mission, we are investing in health-focused product development and building a stronger platform for scale. We believe these initiatives will position Edible Garden as a next-generation sustainable food company with multiple high-growth revenue streams.”

“Looking ahead, we believe the most challenging phase of this transformation is behind us. We’ve built a more resilient organization—one that is better-positioned to capture growth across both fresh and non-perishable categories—and we are on our way toward achieving our goal of long-term, sustainable profitability. We’re excited about the opportunities that lie ahead for Edible Garden.”

Financial Results for the Three Months Ended September 30, 2025

Revenue increased 9% to $2.8 million, compared to $2.6 million in the third quarter of 2024. The 9% growth was primarily driven by strong performance across our shelf-stable product portfolio, including Kick.Sports Nutrition, Vitamin Whey, Pulp, and Pickle Party. With the strategic exit from floral and lettuce categories now complete, this quarter reflects the strength and resilience of our repositioned portfolio.

Gross profit totaled approximately $0.3 million, compared to $0.7 million in the prior-year quarter, reflecting higher labor, freight, and raw material costs, as well as inflationary pressures within the nutraceutical supply chain.

Selling, general and administrative expenses were $3.8 million, compared to $2.2 million in the same period last year, primarily due to higher depreciation expenses related to the assets purchased from Natural Shrimp and the associated right of use, legal, audit and accounting expenses

The Company refinanced its outstanding debt, securing a lower interest rate and more favorable terms. This refinancing is expected to reduce annual interest expense and reduce financing cash outflows, providing greater financial flexibility to support the Company’s strategic initiatives and growth objectives. Net loss was $4.0 million, compared to a net loss of $2.1 million in the third quarter of 2024.

The complete financial results for the quarter ended September 30, 2025, are available in the Company’s Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission and available at: www.sec.gov.  

Conference Call

Edible Garden will host a conference call today at 8:00 A.M. Eastern Time to discuss the Company’s financial results for the quarter ended September 30, 2025, as well as the Company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll-free +1 808-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 547767. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2914/53224 or on the investor relations section of the Company’s website at https://ediblegardenag.com/presentations/.

A webcast replay will be available on the investor relations section of the Company’s website through November 14, 2026. A telephone replay will be available approximately one hour following the call, through November 28, 2025, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 53224.

ABOUT EDIBLE GARDEN®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering locally grown, organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired® next-generation farming model. Available in over 5,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, a leading AgriFoodTech organization, and is a Giga Guru member of Walmart’s Project Gigaton sustainability initiative. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way® and Vitamin Whey®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.

For Pulp products, visit https://www.pulpflavors.com.

For Vitamin Whey® products, visit https://vitaminwhey.com.

For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/

Watch the Company’s latest corporate video here.

Forward-Looking Statements

This press release contains forward-looking statements, including with respect to the Company’s ability to improve its financial results, the Company’s growth strategies, the Company’s ability to expand into new product lines, and its performance as a public company. The words “believe,” “design,” “expect,” “potential,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including market and other conditions and the Company’s ability to improve its financial performance and achieve its growth objectives, and other factors set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s annual report on Form 10-K for the year ended December 31, 2024 and subsequent quarterly reports on Form 10-Q. Actual results might differ materially from those explicit or implicit in the forward-looking statements. The Company undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations, except as required by law.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
[email protected] 

(tables follow)

EDIBLE GARDEN AG INCORPORATEDUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except shares and par value)        September 30, December 31,   2025  2024        ASSETS       Current assets:      Cash $828  $3,530  Accounts receivable, net  1,661   1,968  Inventory, net  1,718   1,544  Prepaid expenses and other current assets  649   335          Total current assets  4,856   7,377          Property, equipment and leasehold improvements, net  10,648   3,145  Operating lease right-of-use assets  4,205   1,202  Finance lease right-of-use assets  81   114  Intangible assets, net  308   43  Other assets  34   34          TOTAL ASSETS $20,132  $11,915          LIABILITIES AND STOCKHOLDERS' EQUITYLIABILITIES:       Current liabilities:       Accounts payable and other accrued expenses $3,699  $4,018  Current maturities of operating lease liabilities  223   212  Current maturities of finance lease liabilities  44   41  Short-term debt, net of discounts  2,059   1,939  Derivative liability  79   -          Total current liabilities  6,104   6,210          Long-term liabilities:       Long-term debt, net of discounts  239   544  Long-term operating lease liabilities  824   992  Long-term finance lease liabilities  42   75          Total long-term liabilities  1,105   1,611          Total liabilities  7,209   7,821          COMMITMENTS AND CONTINGENCIES (Note 13)               STOCKHOLDERS' EQUITY:       Common stock ($0.0001 par value, 100,000,000 shares authorized, 3,083,899 and 1,065,402 shares outstanding as of September 30, 2025 and December 31, 2024, respectively)(1)  -   -  Preferred stock ($0.0001 par value, 10,000,000 shares authorized, 15,154 and no shares outstanding as of September 30, 2025 and December 31, 2024, respectively)  15,154   -  Additional paid-in capital  50,492   44,946  Obligation to issue shares  -   459  Accumulated deficit  (52,723)  (41,311)         Total stockholders' equity  12,923   4,094          TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $20,132  $11,915          (1)Adjusted to reflect the stock splits as described in Note 1.        EDIBLE GARDEN AG INCORPORATED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  (In thousands, except share and per-share information)                               Three Months Ended September 30  Nine Months Ended September 30    2025  2024  2025  2024              Revenue $2,817  $2,584  $8,681  $9,985  Cost of goods sold  2,544   1,885   7,686   7,696                Gross profit  273   699   995   2,289                Selling, general and administrative expenses  3,831   2,189   11,073   8,823  Gain on sale of asset  -   -   (1)  -  Loss from operations  (3,558)  (1,490)  (10,077)  (6,534)               Other income (expenses)             Interest expense, net  (387)  (409)  (1,216)  (944) Gain (Loss) from extinguishment of debt  (109)  (164)  (223)  (498) Other income / (loss)  -   -   95   4  Gain on change in derivative liability  9   -   9   -  Total other income (expenses)  (487)  (573)  (1,335)  (1,438)               NET LOSS  $(4,045) $(2,063) $(11,412) $(7,972)               Deemed dividend on warrants  -   -   (9,833)  -  NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $(4,045) $(2,063) $(21,245) $(7,972)                             Net Income / (Loss) per common share - basic and diluted (1) $(1.38) $(16.32) $(9.95) $(118.25)               Weighted-Average Number of Common Shares Outstanding - Basic and Diluted (1)  2,934,311   126,416   2,134,797   67,416                (1) Adjusted to reflect the stock splits as described in Note 1.
                               

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Opendoor Technologies (NASDAQ:OPEN ) has become the preeminent meme stock lately, rallying from penny stock territory this past summer to one where its shares have rallied more than tenfold.

Alibaba is attempting integrate e-commerce and improved AI functions. Photographer: Paul Yeung/Bloomberg

© 2025 Bloomberg Finance LP

Alibaba Group Holding is preparing a major redesign of its flagship mobile AI app, aiming to bring it closer in look and function to OpenAI’s ChatGPT.

The move is part of a broader push to try and narrow the gap with its major Asian competitors and eventually to build a business around individual users, according to Bloomberg.

The company is expected begin by updating its current Tongyi apps on iOS and Android and adopting a new name, Qwen, drawn from the company’s widely recognized AI model. Over the coming months, Alibaba is expected to layer in more agent-style capabilities that can help users shop across services such as Taobao.

The relaunch marks one of Alibaba’s most ambitious attempts to build consumer revenue around artifical intelligence. The online giant, like rivals ranging from startup Minimax to TikTok owner ByteDance, has been racing to release more sophisticated models in the hope of matching the performance of leading AI players such as OpenAI and DeepSeek.

The long-term objective is to turn Qwen into a fully capable AI agent; a goal that has become generally central to the retail industry on both sides of the Pacific.

Alibaba also intends to introduce a version of Qwen for international markets, and according to reports over 100 engineers from across the organization have been assigned to the redesign, part of the broader AI investment effort that Alibaba Chief Executive Eddie Wu trailed in September.

Alibaba Sees Qwen Trail RivalsQwen currently lags ByteDance’s Doubao and Tencent Holdings’ Yuanbao in user traction. By weaving in shopping-related tools, Alibaba appears to be leaning on its traditional strength in e-commerce to draw more people to the app, especially as e-commerce evolves towards click-from-AI models.

MORE FOR YOU

The company currently offers both the Tongyi consumer apps and a separate Qwen Chat app on mobile, though the latter has fewer features. It is understood that the intention is to unify these under the Qwen name and establish it as the primary product.

Alibaba wants to build on the success of its consumer connections.

getty

The revamped app will remain free for the present time, but building a substantial user base could give Alibaba scope to charge for consumer services later and stand out in an increasingly crowded market.

Alibaba is also preparing to overhaul the way cross-border payments move through its $35 billion e-commerce ecosystem, betting on tokenization as the next major leap in global settlement infrastructure.

Alibaba Talks TokenizationDuring an interview with CNBC, Alibaba President Kuo Zhang said that the company is building a new payment network that uses a tokenized, stablecoin-like system to simplify international B2B transactions. The company is hoping to launch the platform by the end of the year.

In September, CEO Wu outlined plans for new models and a full AI stack, signaling Alibaba’s ambition to develop both consumer services and the underlying infrastructure, including chips.

Alibaba has previously tried before to bring its AI tools directly to the public. It overhauled its Quark search app earlier this year with the goal of turning it into a general-purpose AI assistant, and that app will continue to operate.

In its most recent quarter, Alibaba reported triple-digit growth in AI-related offerings, and its cloud business exceeded expectations, making it the company’s fastest-growing division.

Google must pay the German price comparison platform Idealo approximately 465 million euros ($542 million) in damages for market abuse, a Berlin court has ruled.

Burberry Group PLC (LSE:BRBY) has seen a modest uplift in broker expectations after analysts at Deutsche Bank highlighted signs of sequential progress in the company’s strategy.

The German bank's London-based analysts nudged up their price target to 1550p from 1500p and repeated a 'Buy' rating.

DB said inventory is lower, full-price sales are improving, and cost efficiencies are taking hold.

It added that the brand is gaining momentum, with clearer messaging supporting stronger sell-through across outerwear and scarves and spreading into other categories.

The first-half performance delivered a small beat, helped by stronger constant-FX sales. The wholesale order book was described as encouraging, with brand partners increasing commitments after recent sell-through trends. The broker noted management's confidence in a step-up in constant-FX sales in the second half, together with October trading of about 2%, which DB said had provided reassurance.

Forecasts have been nudged higher. The broker lifted its FY26 EBIT estimate by one percent to £150 million and raised its FY27 estimate by seven percent to £264 million.

Stocks might still be the preferred investment of choice. But exchange traded funds (ETFs) are quickly gaining ground.

KUALA LUMPUR, Malaysia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company, today announced that its subsidiary, Tadaa Technologies Sdn Bhd (“Tadaa”), has been appointed as the exclusive partner and treasury manager for 200 million UNIRWA tokens, with a projected value of USD 100 million, supporting the tokenization of real-world assets in real estate and hospitality across Southeast Asia.

This marks a significant milestone in the Company’s expansion into blockchain-based financial solutions and reinforces its commitment to building a transparent, regulated, secure, and safe digital asset ecosystem that generates sustainable revenue.

UNIRWA Token and OXI Wallet Integration

The UNIRWA token will be available on the upcoming OXI Wallet, scheduled for release in 1H 2026. The OXI Wallet is designed to provide regulated, secure, and transparent access to real-world asset-backed digital tokens and will play a crucial role in providing a secure platform, along with technology support and token structuring for UNIRWA.

Under the agreement, Tadaa will oversee and provide tokenization solutions and modelling services, including but not limited to assets classification, structure, technical and operational flows, regulatory and compliance framework advisory in connection with the UNIRWA token. Upon commencing the project, this integrated structure will enable Tadaa to maintain token stability and facilitate cross-platform utility, including the tokenized real-world assets exchange with real estate and hospitality assets backed transactions.

Revenue Model

As the exclusive partner and treasury manager for UNIRWA, Tadaa plans to develop three potential revenue channels within its digital asset business:

Management Returns — Income generated from managing and allocating token reserve assets, smart contract development, and technology infrastructure using compliant, yield-generating instruments.Transaction and Settlement Fees — Fees collected from token issuance, conversions, redemptions, and cross-border payments within the OXI Wallet platform.Platform Utility Revenues — Ecosystem service fees related to compliance facilitation and real-world asset tokenization solutions.
Together, these revenue streams are expected to strengthen the Company's fintech business and position to capitalize on the growing real-world asset tokenization market.

Market Growth and Industry Potential

Investor demand for asset-backed digital tokens continues to accelerate across Southeast Asia, as both individual and institutional participants seek regulated exposure to real-world assets through blockchain technology. This trend, coupled with the projections from industry reports, indicates a significant growth potential for the asset tokenization market in the coming years.

According to a joint report by Boston Consulting Group (BCG) and ADDX (2024), the global asset tokenization market is projected to reach USD 16.1 trillion by 2030, underscoring the immense potential of professionally managed tokenized assets.

Additionally, Citi Global Perspectives & Solutions (Citi GPS, March 2023) forecasts that the tokenization of financial and real-world assets could drive blockchain's growth, with private markets expected to expand 80-fold, reaching nearly USD 4 trillion in value by 2030.

“By managing the UNIRWA token, the Company aims to contribute to a structured, transparent, and secure digital asset ecosystem,” said Carlson Thow, Chief Executive Officer of Treasure Global Inc. “This initiative reflects our strategic expansion into regulated blockchain finance, building a foundation for scalable, recurring revenue growth through digital asset management and fintech innovation.”

“UNIRWA provides a professionally managed, asset-backed token framework for investors seeking transparent exposure to real-world assets,” said Eugene, Project Manager for UNIRWA. “Its structure combines reserve-backed stability with compliance, and auditing is designed to promote long-term value and investor confidence within the ecosystem.”

Revenue and Growth Outlook

This marks Treasure Global’s first exclusive partnership and treasury management collaboration in real-world asset (RWA) tokenization through its subsidiary Tadaa Technologies and the upcoming OXI Wallet platform. Through compliant RWA token structures, Treasure Global aims to establish recurring income streams, expand its fintech offerings, and reinforce its position in Southeast Asia’s rapidly growing digital asset economy.

Sources

Boston Consulting Group (BCG) & ADDX, Global Asset Tokenization Market Report 2024Citi Global Perspectives & Solutions (Citi GPS), Money, Tokens and Games: Blockchain’s Next Billion Users and Trillions in Value (March 2023) About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of June 2025, ZCITY has attracted over 2.7 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the Company’s ability to expand its e-commerce platform and F&B distribution business, customer acceptance of new products and services, changes in economic conditions affecting its operations, the outcome of partnership discussions, the impact of global health crises, supply chain disruptions, competition, and regulatory risks related to data privacy and security. Additional risks include volatility in digital asset markets, potential vulnerabilities in custodial security, and evolving global and domestic regulatory frameworks applicable to blockchain technologies. These risks, along with other factors, are discussed in more detail in the Company’s filings with the U.S. Securities and Exchange Commission.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
[email protected]

Indian state refiners have awarded their first joint, long-term tenders to Chevron , Phillips 66 and TotalEnergies Trading SA to import U.S. liquefied petroleum gas in 2026, two trade sources with knowledge of the matter said.

November 14, 2025 6:08 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - November 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jamf Holding Corp.'s (NASDAQ: JAMF) board of directors for potential breaches of their fiduciary duties to shareholders in connection with a potential take-private sale of Jamf that would cash out every stockholder for $13.05 per share.

If you are a current shareholder of Jamf, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jamf-holding-corp-take-private-investigation.

Why is Jamf being Investigated?

On October 29, 2025, Jamf announced that it had agreed to be acquired by Francisco Partners Management, L.P. ("FP") for $13.05 per share. This price may represent an unfairly low price being paid to Jamf stockholders and may be the result of conflicts of interest between the Jamf board of directors, FP, and Vista Equity Partners ("Vista").

Vista exercises significant power over Jamf, owning 34.4% of the outstanding stock, and having contractual rights to appoint four out of the nine members of the Jamf board of directors. The board of directors of Jamf did not employ an independent special committee to evaluate the transaction. While the deal is conditioned on a stockholder vote, the Company has not excluded Vista from that vote.

BFA Law is investigating Jamf's board of directors and Vista to ascertain whether they have breached fiduciary duties to Jamf stockholders in connection with the contemplated transaction.

Click here for more information: https://www.bfalaw.com/cases/jamf-holding-corp-take-private-investigation.

What Can You Do?

If you are a current holder of Jamf you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jamf-holding-corp-take-private-investigation

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jamf-holding-corp-take-private-investigation

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274376

November 14, 2025 6:08 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - November 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned MacMahon v. Stride, Inc., et al., No. 1:25-cv- 02019.

Why is Stride Being Sued for Securities Fraud?

Stride is an education technology company that provides an online platform to students throughout the U.S. During the relevant period, Stride stated it was seeing "increasing growth in our business," "in-year strength in demand" for its products and services, and that its customers and potential customers "continue to choose us in record numbers."

As alleged, in truth, Stride had inflated enrollment numbers by retaining "ghost students," ignored compliance requirements for its employees, and had "poor customer experience" that resulted in "higher withdrawal rates," "lower conversion rates," and had driven students away.

Why did Stride's Stock Drop?

On September 14, 2025, a report stated that a complaint had been filed against Stride for fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct. It claimed Stride inflated enrollment numbers by retaining "ghost students" on rolls to secure state funding and ignored compliance requirements, including background checks and licensure laws for its employees. This news caused the price of Stride stock to drop $18.60 per share, or more than 11%, from a closing price of $158.36 per share on September 12, 2025, to $139.76 per share on September 15, 2025.

Then, on October 28, 2025, Stride admitted that "poor customer experience" resulted in "higher withdrawal rates," "lower conversion rates," and drove students away. Stride estimated the impact caused approximately 10,000-15,000 fewer enrollments and stated that, because of this, its outlook is "muted" compared to prior years. This news caused the price of Stride stock to drop $83.48 per share, or more than 54%, from a closing price of $153.53 per share on October 28, 2025, to $70.05 per share on October 29, 2025.

Click here for more information: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

What Can You Do?

If you invested in Stride you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274380